14TH ALA Conference: MLS® and lymphoedema: the focus of a seminar

09 June 2022 - Trade fairs & Congresses -

MLS® Laser Therapy and its devices are among the protagonists of the “14th ALA Conference” (Hobart – Tasmania) thanks to the participation of the local distributor Heal With Laser, a long-term partner of the Australian Lymphology Association, sponsor of the Conference and organiser of a pre-meeting speed on the topic “Using laser therapy to treat and manage lymphoedema: proof and practice”. 

The seminar, by Dr. Kate Perkins, owner of “Cancer Rehabilitation and Lymphatic Solutions” and a long-time user of the M6 device, presented an MLS® treatment method combined with other methods and some clinical cases solved using ASA-branded therapy.

“Already in the past, Dr. Sharon Tilley, Physiotherapist at the “Lymphoedema and Laser Therapy clinic” in Adelaide, has pointed out how MLS® could be a valuable support in the treatment of lymphoedema. Dr. Perkins’ speech - explains Giacomo Granozio, ASA Area Manager – further confirms its value, also emphasised by an articulate case history presented during the meeting”.

 

ALA 2022 pre-conference workshop on MLS Laser Therapy and lymphoedema
Lymphoedema and MLS Laser Therapy - Kate Perkins workshop

Catherine Norton, CEO and founder of Heal With Laser, adds:

“During the workshop, prominence was also given to the research carried out by the team from Hasselt University, consisting of Jolien Robijns, Joy Lodewijckx and Jeroen Mebis: we consider their research to be a guiding light in this sector. While photobiomodulation is widely recognised for the effective treatment of wounds, for the reduction of musculoskeletal pain and for the accelerations of healing processes, the innovative use of MLS® for the treatment of issues related to COVID-19 was also discussed during the seminar, as proven by Dr. Scott Sigman's clinical study. His work was truly pioneering and has allowed many European specialists to replicate his insight: laser therapy is now successfully used to treat post-COVID patients”.

You might also be interested in ...

See all articles

Supportive Care in Cancer - Springer
blog - 04/04/2022
M6 in the prevention of peripheral neuropathy caused by chemotherapy: a study
The clinical trial investigated the efficacy and safety of photobiomodulation therapy (PBMT) delivered by laser source (M6) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in...
Effect of NIR Laser Therapy by MLS‐MiS Source on Fibroblast Activation by Inflammatory Cytokines in Relation to Wound Healing
blog - 12/04/2021
Research detects the anti-inflammatory effect of MiS on cells and molecules
The ASA device have an important anti-inflammatory effect, but it is also effective in controlling fibroblast activation induced by IL‐1β and TNF‐α, probably responsible for a detrimental effect on...
M8 laser treatment for pain due to COVID-19
blog - 09/04/2021
Journal Of Inflammation Research: MLS® Laser Therapy and the consequences of interstitial pneumonia caused by COVID-19
The results actually showed that patients undergoing MLS® Laser Therapy had a rapid recovery
Press - 15/12/2025
ASA: XMAS(A) PARTY 2025 ‘GEN TALK & TV ICONS PARTY’
The Vicenza-based company closed out 2025 with a celebration of diversity. For the holiday season, ASA invited its staff to take part in a ‘journey into the value of intergenerational dialogue’,...
Team ASA @ Kin'Expo 2025
News - 12/12/2025
ASA at Kin'Expo Marseille: focus on devices and clinical updates
ASA participated in Kin'Expo Marseille 2025, the final annual event in the French national physiotherapy circuit, confirming its commitment towards strengthening the brand's presence and supporting...
Press - 26/11/2025
Gender-based violence vs inclusivity: ASA & Women For Freedom united in a joint awareness-raising initiative
To mark the month dedicated to combating violence against women, the two Vicenza-based entities have joined forces to promote a culture of acceptance and gender equality